Indian drug maker Lupin said it has entered into a partnership with Shenzhen Foncoo Pharmaceutical Co. (Foncoo), to sell complex generic medicines in the Chinese market. According to Dr. Fabrice Egros, President – Growth Markets, Lupin, his  company continues to invest in key growth markets and with China’s growing commitment to affordable and accessible healthcare, Lupin is committed to serving the healthcare needs in that market by providing quality generic and complex generic products. 

“We expect the launch of our first product in China soon. We will also continue exploring more opportunities to work with Lupin for providing more and more high-valued and complex medicines to the Chinese physicians and patients,” said Peng Yan, General Manager at Fonco, in a statement after signing the partnership.